[Skip to the reading](https://sdpeptides.com/#sd-main)

[SD Peptides](/)

[Why an average leaves questions](/#why-an-average-is-incomplete) · [How we read a reported range](/reading-ranges) · [What the human results can tell us](/human-results)

# One average at SD Peptides can’t tell everyone’s story.

An average is handy. It can also hide quite a crowd. At SD Peptides, we look at spread: how much the results differ around that average.

We want to know what happened to the people on either side of the headline. A hopeful result can be real without being everyone’s experience.

Teaching examples without numbers — hypothetical descriptions, not study results.

The group stays fairly close together.

Imagine most people report a similar change. The average fits their experience fairly well.

The average hides a much wider mix of experiences.

Imagine some people change a lot and others very little. The average leaves plenty out.

The same encouraging average could sit between people who improve, people who barely change and people who feel worse.

Imagine a helpful-sounding headline with very different experiences behind it.

## Different paces share the same path

![Several adults warm up at different paces along the same park path.](/sd-spread-cc9456f6a3a9/different-paces.webp)

A shared direction can contain different experiences. This is an everyday illustration of variation, not a study group or a treatment result.

## Why an average is incomplete

The descriptions above are made-up teaching examples. Their underlines don’t stand for amounts. They’re a way to picture different possibilities, without pretending we have results to plot.

An average sums up a group. It doesn’t tell us whether most people had a similar experience or a very different one. In a semaglutide trial, [the average weight change and the share reaching a weight-loss goal](https://pubmed.ncbi.nlm.nih.gov/33567185/) give us two ways to look at the result. Neither tells the whole story alone.

We also want to know who was studied. [In rats, BPC-157 improved healing after an Achilles tendon was cut](https://pubmed.ncbi.nlm.nih.gov/14554208/). That’s interesting, but it doesn’t tell us whether a person will get back to climbing stairs sooner. The word “research” can’t do that extra work for us.

## Reading a reported range responsibly

A range looks helpful. First, though, we need to know what its ends mean. Are they the smallest and largest individual changes, or uncertainty about a group average? Those aren’t the same thing.

Our [page on reading ranges](/reading-ranges) walks through that distinction. If a paper leaves individual results out, we leave the gap open too. Guessing would make the page tidier and the answer worse.

Safety needs the same care. The [FDA found no published studies giving TB-500 to people](https://www.fda.gov/media/193349/download). That leaves human risks unknown. It doesn’t give us a reassuring safety record.

## Pick the question on your mind

For a human trial, try [what semaglutide’s results can tell us](/human-results). For healing claims, read [where BPC-157 and TB-500 evidence stops](/repair-claims). For GHK-Cu, MOTS-c and KPV, follow [the gap between cells and people](/cell-to-person).

We help with the reading. Personal treatment questions belong with a licensed U.S. clinician who can assess your situation. These pages give no medical advice or product recommendations.


We explain the room around a result; this is a research guide, not a clinic, pharmacy or seller.

© 2026 SD Peptides

[What the human results can tell us](/human-results)

[The missing steps in healing claims](/repair-claims)

[The distance from a cell to a person](/cell-to-person)

[How we read a reported range](/reading-ranges)

[Follow a sentence back to its source](/references)

[Why we make room around the average](/about)

[What a research question can ask here](/contact)